- Home
- DXC vs ZLAB Comparison
DXC vs ZLAB Comparison
Compare DXC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXC
- ZLAB
- Stock Information
- Founded
- DXC 1959
- ZLAB 2013
- Country
- DXC United States
- ZLAB China
- Employees
- DXC N/A
- ZLAB N/A
- Industry
- DXC EDP Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- DXC Technology
- ZLAB Health Care
- Exchange
- DXC Nasdaq
- ZLAB Nasdaq
- Market Cap
- DXC 3.5B
- ZLAB 3.4B
- IPO Year
- DXC N/A
- ZLAB 2017
- Fundamental
- Price
- DXC $19.56
- ZLAB $33.78
- Analyst Decision
- DXC Hold
- ZLAB Strong Buy
- Analyst Count
- DXC 8
- ZLAB 3
- Target Price
- DXC $21.38
- ZLAB $55.00
- AVG Volume (30 Days)
- DXC 1.1M
- ZLAB 752.8K
- Earning Date
- DXC 02-04-2025
- ZLAB 02-27-2025
- Dividend Yield
- DXC N/A
- ZLAB N/A
- EPS Growth
- DXC N/A
- ZLAB N/A
- EPS
- DXC N/A
- ZLAB N/A
- Revenue
- DXC $13,088,000,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- DXC N/A
- ZLAB $49.04
- Revenue Next Year
- DXC N/A
- ZLAB $46.80
- P/E Ratio
- DXC N/A
- ZLAB N/A
- Revenue Growth
- DXC N/A
- ZLAB 35.01
- 52 Week Low
- DXC $14.79
- ZLAB $13.48
- 52 Week High
- DXC $24.83
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- DXC 39.15
- ZLAB 79.95
- Support Level
- DXC $19.69
- ZLAB $30.61
- Resistance Level
- DXC $21.35
- ZLAB $33.00
- Average True Range (ATR)
- DXC 0.97
- ZLAB 1.32
- MACD
- DXC -0.17
- ZLAB 0.58
- Stochastic Oscillator
- DXC 1.87
- ZLAB 86.34
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.